NCT00439465 · OUTCOME

Assessment of Disease Response to Treatment

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma · Source last updated 2019-03-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From initiation of treatment on protocol until Day 100

What was measured

To establish the disease response of myeloma patients treated with high dose melphalan, APBSCT\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.

Groups in this outcome

Ex-vivo Expanded Effector Cells

Infusing IL-2 and GM-CSF post-HCST Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Ex-vivo Expanded Effector Cells	19

Reported measurements

Source class 1

Complete Response

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ex-vivo Expanded Effector Cells	12	Not reported	Not reported	Not reported	Not reported

Very Good Partial Response

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ex-vivo Expanded Effector Cells	5	Not reported	Not reported	Not reported	Not reported

Partial Response

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ex-vivo Expanded Effector Cells	1	Not reported	Not reported	Not reported	Not reported

Progressive disease

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ex-vivo Expanded Effector Cells	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
12
title
Complete Response
measurements
group Id
OG000
value
5
title
Very Good Partial Response
measurements
group Id
OG000
value
1
title
Partial Response
measurements
group Id
OG000
value
1
title
Progressive disease

denoms

counts
group Id
OG000
value
19
units
Participants

description

To establish the disease response of myeloma patients treated with high dose melphalan, APBSCT\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.

groups

description
Infusing IL-2 and GM-CSF post-HCST Ex-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
id
OG000
title
Ex-vivo Expanded Effector Cells

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

From initiation of treatment on protocol until Day 100

title

Assessment of Disease Response to Treatment

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice